The invention also discloses application of serine integration factor 2 in MLL fusion gene leukemia

A serine and leukemia technology, applied in the field of biomedicine, can solve the problems of easy recurrence, complicated pathogenesis, poor prognosis, etc., and achieve the effect of prolonging the survival period and inhibiting cell proliferation

Active Publication Date: 2021-04-16
SUN YAT SEN UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to its complex pathogenesis, poor prognosis, and easy recurrence, the treatment of this type of leukemia still faces severe challenges, and the five-year survival rate is relatively low
Currently, MLL-R leukemia cells are resistant to leukemia chemotherapy drugs, such as L-asparaginase and prednisone, which is also consistent with the poor prognosis of MLL-R leukemia
There are no relevant reports on the function of serine integrator 2 or its family proteins in MLL-R leukemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The invention also discloses application of serine integration factor 2 in MLL fusion gene leukemia
  • The invention also discloses application of serine integration factor 2 in MLL fusion gene leukemia
  • The invention also discloses application of serine integration factor 2 in MLL fusion gene leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Serine Integration Factor 2 (SERINC2) Expression Analysis

[0037] The present invention discovers a gene SERINC2 that is specifically highly expressed in MLL-R leukemia and lowly expressed in normal physiological conditions and other types of leukemia. This gene encodes five different transmembrane proteins ( figure 1 A). Among them, transcript 1 is an 11 transmembrane protein ( figure 1 B). Its nucleotide sequence is shown in SEQ ID NO:1; its amino acid sequence is shown in SEQ ID NO:2.

[0038] In order to further confirm the expression specificity of SERINC2 in MLL-R leukemia, we collected a batch of bone marrow samples from the First Affiliated Hospital of Sun Yat-sen University for detection and analysis, including 51 cases of MLL wild-type (MLL-wt) leukemia samples, And 26 cases of MLL-R leukemia samples. All sample collection was approved by the Ethics Committee of Sun Yat-Sen University and informed consent was obtained from the patients. SERINC...

Embodiment 2

[0042] Example 2 Functional identification of SERINC2 in MLL-R leukemia

[0043] In order to solve the core problem of SERINC2 participating in the regulation of MLL-R leukemia, we intend to further study the function of SERINC2 on MLL-R leukemia. Therefore, we selected MLL-R leukemia cell lines, RS4-11 (MLL-AF4) and MV4-11 (MLL-AF4) as the research objects. Two different siRNA sequences were designed for SERINC2 by siRNA interference technology.

[0044] Forward sequence of siRNA-1: 5'-GGTCAGCCTATCCAGTAT dTdT-3' (SEQ ID NO: 5);

[0045] Reverse sequence of siRNA-1: 5'-CCAGTCGGGATAGGTCATA dTdT-3' (SEQ ID NO: 6);

[0046] Forward sequence of siRNA-2: 5'-TGACGCTCACCAACTGGTA dTdT-3' (SEQ ID NO: 7);

[0047] Reverse sequence of siRNA-2: 3'-ACTGCGAGTGGTTGACCAT dTdT-5' (SEQ ID NO: 8).

[0048] In the above two MLL-R leukemia cell lines, SERINC2 was knocked out respectively, and the effect of SERINC2 knockdown and expression in MLL-R leukemia was detected by qRT-PCR, and the cell...

Embodiment 3

[0059] Example 3 SERINC2 regulates the mTOR pathway

[0060] SERINC2 is a protein of the serine integrator family, which was identified and named in 2005 and proved to be related to serine integration in lipid synthesis. The present invention finds that SERINC2 is localized on autophagy lysosomes ( Figure 5A). SERINC2 is a member of the amino acid transporter family, therefore, we speculate that on the autophagosome membrane, SERINC2 mediates the activation of the mTOR pathway by sensing amino acid changes. To verify our speculation, we knocked down SERINC2 using shRNA in RS4-11 and MV4-11, and detected the phosphorylation level of S6K protein directly downstream of mTOR. We used amino acid starvation re-induction experiments, in which 1640 medium without amino acids was used for starvation for 50 minutes, and medium containing all amino acids was added for induction for 30 minutes. First of all, this study first found that SERINC2 is localized on autolysosomes and its loc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a protein serine integration factor 2 in MLL fusion gene leukemia. A large number of leukemia patient samples are detected through real-time quantitative PCR, and it is found that SERINC2 in MLL fusion gene leukemia patients is remarkably high in expression; and then the expression of SERINC2 is knocked down, so that the survival of MLLR leukemia cells can be remarkably inhibited; meanwhile, the result of a mouse leukemia model shows that the life cycle of a model mouse can be remarkably prolonged by knocking down the expression of the SERINC2, and the SERINC2 can be used as a diagnosis marker and/or a treatment target to play a role in MLLR leukemia. Therefore, the invention can provide a new accurate treatment strategy and genetic resource for targeted treatment of MLL fusion gene leukemia, and has important theoretical significance and application value.

Description

technical field [0001] The invention relates to the technical field of biomedicine, and more specifically, relates to the application of serine integration factor 2 in MLL fusion gene leukemia. Background technique [0002] MLL fusion gene leukemia, MLL (mixed-lineage leukemia) gene rearrangement leukemia (MLL-rearranged leukemia, MLL-R leukemia). Due to its complex pathogenesis, poor prognosis, and easy recurrence, the treatment of this type of leukemia still faces severe challenges, and the five-year survival rate is relatively low. Currently, MLL-R leukemia cells are resistant to leukemia chemotherapy drugs, such as L-asparaginase and prednisone, which is also consistent with the poor prognosis of MLL-R leukemia. Therefore, finding the pathogenesis and molecular markers of MLL-R leukemia is of great significance for the development of prognostic molecules and therapeutic targets for this type of leukemia. [0003] In MLL-R leukemia, the mTOR (Mammalian target of rapamyc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12N15/11A61K31/7105A61K39/395A61P35/02
Inventor 陈月琴方可王文涛黄蔚
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap